Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 10.43
ALXN's Cash to Debt is ranked higher than
70% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. ALXN: 10.43 )
ALXN' s 10-Year Cash to Debt Range
Min: 0.54   Max: No Debt
Current: 10.43

Equity to Asset 0.72
ALXN's Equity to Asset is ranked higher than
77% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALXN: 0.72 )
ALXN' s 10-Year Equity to Asset Range
Min: 0.27   Max: 0.93
Current: 0.72

0.27
0.93
Interest Coverage 128.41
ALXN's Interest Coverage is ranked higher than
60% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALXN: 128.41 )
ALXN' s 10-Year Interest Coverage Range
Min: 14.38   Max: 9999.99
Current: 128.41

14.38
9999.99
F-Score: 4
Z-Score: 21.04
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 34.04
ALXN's Operating margin (%) is ranked higher than
96% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. ALXN: 34.04 )
ALXN' s 10-Year Operating margin (%) Range
Min: -10370.21   Max: 35.65
Current: 34.04

-10370.21
35.65
Net-margin (%) 16.30
ALXN's Net-margin (%) is ranked higher than
91% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. ALXN: 16.30 )
ALXN' s 10-Year Net-margin (%) Range
Min: -10220.86   Max: 76.31
Current: 16.3

-10220.86
76.31
ROE (%) 10.62
ALXN's ROE (%) is ranked higher than
90% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. ALXN: 10.62 )
ALXN' s 10-Year ROE (%) Range
Min: -160.7   Max: 42.88
Current: 10.62

-160.7
42.88
ROA (%) 7.62
ALXN's ROA (%) is ranked higher than
91% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. ALXN: 7.62 )
ALXN' s 10-Year ROA (%) Range
Min: -43.83   Max: 37.53
Current: 7.62

-43.83
37.53
ROC (Joel Greenblatt) (%) 155.90
ALXN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. ALXN: 155.90 )
ALXN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -955.65   Max: 155.9
Current: 155.9

-955.65
155.9
Revenue Growth (%) 38.70
ALXN's Revenue Growth (%) is ranked higher than
94% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. ALXN: 38.70 )
ALXN' s 10-Year Revenue Growth (%) Range
Min: -70.5   Max: 498.1
Current: 38.7

-70.5
498.1
EBITDA Growth (%) 46.50
ALXN's EBITDA Growth (%) is ranked higher than
98% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. ALXN: 46.50 )
ALXN' s 10-Year EBITDA Growth (%) Range
Min: -10.1   Max: 72.8
Current: 46.5

-10.1
72.8
EPS Growth (%) 34.70
ALXN's EPS Growth (%) is ranked higher than
95% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. ALXN: 34.70 )
ALXN' s 10-Year EPS Growth (%) Range
Min: -15.3   Max: 77.3
Current: 34.7

-15.3
77.3
» ALXN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ALXN Guru Trades in Q1 2013

Andreas Halvorsen 9,462,442 sh (+135.72%)
Paul Tudor Jones 5,600 sh (+40%)
Jeremy Grantham 69,042 sh (+20.07%)
Frank Sands 8,420,336 sh (+4.23%)
Louis Moore Bacon Sold Out
Columbia Wanger Sold Out
RS Investment Management Sold Out
Joel Greenblatt Sold Out
Steven Cohen 7,227 sh (-4.91%)
Jim Simons 433,300 sh (-7.32%)
Pioneer Investments 161,000 sh (-39.2%)
» More
Q2 2013

ALXN Guru Trades in Q2 2013

Steven Cohen 89,400 sh (+1137.03%)
Jeremy Grantham 69,727 sh (+0.99%)
Frank Sands 8,424,567 sh (+0.05%)
Jim Simons Sold Out
Paul Tudor Jones 3,800 sh (-32.14%)
Andreas Halvorsen 5,544,949 sh (-41.4%)
Pioneer Investments 30,500 sh (-81.06%)
» More
Q3 2013

ALXN Guru Trades in Q3 2013

Eric Mindich 300,000 sh (New)
Pioneer Investments 84,977 sh (+178.61%)
Steven Cohen 201,270 sh (+125.13%)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Frank Sands 7,540,405 sh (-10.5%)
Andreas Halvorsen 3,454,640 sh (-37.7%)
» More
Q4 2013

ALXN Guru Trades in Q4 2013

Eric Mindich Sold Out
Frank Sands 7,370,601 sh (-2.25%)
Andreas Halvorsen 2,877,008 sh (-16.72%)
Pioneer Investments 30,500 sh (-64.11%)
Steven Cohen 67,536 sh (-66.45%)
» More
» Details

Insider Trades

Latest Guru Trades with ALXN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Frank Sands 2013-09-30 Reduce -10.5%0.27%$94.34 - $117.28 $ 152.2339%7540405
Frank Sands 2013-03-31 Add 4.23%0.11%$83.39 - $102.57 $ 152.2364%8420336
Joel Greenblatt 2013-03-31 Sold Out 0.07%$83.39 - $102.57 $ 152.2364%0
Joel Greenblatt 2012-12-31 New Buy0.07%$87.97 - $118.15 $ 152.2355%12977
Frank Sands 2012-06-30 Add 6.43%0.27%$83.74 - $98.82 $ 152.2367%9739804
George Soros 2012-06-30 Sold Out 0.07%$83.74 - $98.82 $ 152.2367%0
George Soros 2012-03-31 New Buy0.07%$70.29 - $94.31 $ 152.23101%50000
Joel Greenblatt 2011-09-30 Sold Out 0.0882%$47.81 - $66.99 $ 152.23171%0
Joel Greenblatt 2011-06-30 New Buy0.09%$44.61 - $52.195 $ 152.23218%13417
George Soros 2011-06-30 Sold Out $44.61 - $52.195 $ 152.23218%0
George Soros 2011-03-31 Add 90.48%$20.14 - $24.93 $ 152.23576%4000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Alexion Pharmaceuticals Inc

CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares
Alexion Pharmaceuticals Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. The company has a market cap of $20.53 billion; its shares were traded at around $105.00 with a P/E ratio of 59.52 and P/S ratio of 15.89. Alexion Pharmaceuticals Inc. had an annual average earnings growth of 70.6% over the past five years. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 125.40
ALXN's P/E(ttm) is ranked lower than
66% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. ALXN: 125.40 )
ALXN' s 10-Year P/E(ttm) Range
Min: 13.92   Max: 1113.68
Current: 125.4

13.92
1113.68
P/B 13.20
ALXN's P/B is ranked lower than
66% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ALXN: 13.20 )
ALXN' s 10-Year P/B Range
Min: 1.73   Max: 32.18
Current: 13.2

1.73
32.18
P/S 20.50
ALXN's P/S is ranked lower than
63% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. ALXN: 20.50 )
ALXN' s 10-Year P/S Range
Min: 9.66   Max: 567.5
Current: 20.5

9.66
567.5
PFCF 67.70
ALXN's PFCF is ranked lower than
61% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. ALXN: 67.70 )
ALXN' s 10-Year PFCF Range
Min: 40   Max: 99999999.99
Current: 67.7

40
99999999.99
EV-to-EBIT 58.80
ALXN's EV-to-EBIT is ranked lower than
72% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. ALXN: 58.80 )
ALXN' s 10-Year EV-to-EBIT Range
Min: 33   Max: 893.9
Current: 58.8

33
893.9
PEG 2.40
ALXN's PEG is ranked higher than
60% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ALXN: 2.40 )
ALXN' s 10-Year PEG Range
Min: 0.68   Max: 2.64
Current: 2.4

0.68
2.64
Shiller P/E 157.90
ALXN's Shiller P/E is ranked lower than
63% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. ALXN: 157.90 )
ALXN' s 10-Year Shiller P/E Range
Min: 98.32   Max: 655.33
Current: 157.9

98.32
655.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 51.78
ALXN's Price/Net Cash is ranked lower than
87% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. ALXN: 51.78 )
ALXN' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 168.3
Current: 51.78

1.68
168.3
Price/Net Current Asset Value 31.65
ALXN's Price/Net Current Asset Value is ranked lower than
78% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ALXN: 31.65 )
ALXN' s 10-Year Price/Net Current Asset Value Range
Min: 1.68   Max: 126.23
Current: 31.65

1.68
126.23
Price/Tangible Book 19.75
ALXN's Price/Tangible Book is ranked lower than
82% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. ALXN: 19.75 )
ALXN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 34.74
Current: 19.75

1.5
34.74
Price/DCF (Projected) 6.00
ALXN's Price/DCF (Projected) is ranked lower than
61% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. ALXN: 6.00 )
ALXN' s 10-Year Price/DCF (Projected) Range
Min: 4.42   Max: 26.5
Current: 6

4.42
26.5
Price/Median PS Value 1.04
ALXN's Price/Median PS Value is ranked higher than
68% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALXN: 1.04 )
ALXN' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 45.9
Current: 1.04

0.34
45.9
Price/Peter Lynch Fair Value 4.83
ALXN's Price/Peter Lynch Fair Value is ranked lower than
79% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. ALXN: 4.83 )
ALXN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 4.22
Current: 4.83

0.56
4.22
Price/Graham Number 10.21
ALXN's Price/Graham Number is ranked lower than
80% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. ALXN: 10.21 )
ALXN' s 10-Year Price/Graham Number Range
Min: 2.11   Max: 8.91
Current: 10.21

2.11
8.91
Earnings Yield (Greenblatt) 1.70
ALXN's Earnings Yield (Greenblatt) is ranked lower than
61% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ALXN: 1.70 )
ALXN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3
Current: 1.7

0.1
3
Forward Rate of Return (Yacktman) 55.39
ALXN's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. ALXN: 55.39 )
ALXN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.1   Max: 75.3
Current: 55.39

-7.1
75.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AXP.Germany
Alexion Pharmaceuticals, Inc. is a Delaware based company incorporated in 1992 is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in the therapeutic areas of hematology, nephrology, transplant rejection, neurology and ophthalmology. Soliris is a humanized monoclonal antibody that blocks terminal complement activity at the doses currently prescribed. Soliris was approved for the treatment of PNH by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) in 2007 and by Japan's Ministry of Health, Labour and Welfare (MHLW) in 2010, and has been approved in several other territories. The Company competes with large pharmaceutical companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide